about
Antiplatelet Therapy Combinations and Thrombogenicity in Patients with Non-Valvular Atrial Fibrillation.The impact of smoking on post-clopidogrel platelet reactivity in patients with acute myocardial infarction.The impact of generic clopidogrel bisulfate on platelet inhibition in patients with coronary artery stents: results of the ACCEL-GENERIC studyIsolated left main coronary artery spasm detected by multidetector computed tomographyAsymptomatic left ventricular pseudoaneurysm evaluated with multimodality cardiac imaging.A case of spontaneous coronary artery dissection healed by medical treatment: serial findings of coronary angiography, intravascular ultrasound and multi-detector computed tomographyDelayed ventricular septal rupture following blunt chest traumaAdditive beneficial effects of valsartan combined with rosuvastatin in the treatment of hypercholesterolemic hypertensive patientsEffects of Peroxisome Proliferator-Activated Receptor-δ Agonist on Cardiac Healing after Myocardial Infarction.Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy AcPrognostic value of computed tomographic coronary angiography and exercise electrocardiography for cardiovascular eventsCytochrome 2C19 polymorphism and response to adjunctive cilostazol versus high maintenance-dose clopidogrel in patients undergoing percutaneous coronary intervention.Relation between the vasodilator-stimulated phosphoprotein phosphorylation assay and light transmittance aggregometry in East Asian patients after high-dose clopidogrel loading.The concordance and correlation of measurements by multiple electrode and light transmittance aggregometries based on the pre-defined cutoffs of high and low on-treatment platelet reactivity.The optimal threshold of high post-treatment platelet reactivity could be defined by a point-of-care VerifyNow P2Y12 assay.Erratum to: Additive Beneficial Effects of Valsartan Combined with Rosuvastatin in the Treatment of Hypercholesterolemic Hypertensive PatientsCarriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of ClopidogSmoking at least 10 cigarettes per day increases platelet inhibition by clopidogrel in patients with ST-segment-elevation myocardial infarction.Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: Results of the adjunctive cilostazol versus high maintenance dose clopidogrel inInfluence of platelet reactivity and inflammation on peri-procedural myonecrosis in East Asian patients undergoing elective percutaneous coronary intervention.Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype.Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in PatiEverolimus-eluting Xience v/Promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus.Novel role of platelet reactivity in adverse left ventricular remodelling after ST-segment elevation myocardial infarction: The REMODELING Trial.Pharmacodynamic effects of a new fixed-dose clopidogrel-aspirin combination compared with separate administration of clopidogrel and aspirin in patients treated with coronary stents: The ACCEL-COMBO trial.The CYP2C19*2 and CYP2C19*3 polymorphisms are associated with high post-treatment platelet reactivity in Asian patients with acute coronary syndrome.Risk stratification using computed tomography coronary angiography in patients undergoing intermediate-risk noncardiac surgery.Pharmacodynamic efficacy and safety of adjunctive cilostazol loading to clopidogrel and aspirin loading: the results of the ACCEL-LOADING (Accelerated Platelet Inhibition by Cilostazol Loading) study.A head-to-head comparison between 64-slice multidetector computed tomographic and conventional coronary angiographies in measurement of myocardial bridge.Pharmacodynamic effect of clopidogrel therapy and switching to cilostazol in patients with the CYP2C19 loss-of-function allele (ACCEL-SWITCH) study.Association of cytochrome P450 2C19*2 polymorphism with clopidogrel response variability and cardiovascular events in Koreans treated with drug-eluting stents.The cytochrome 2C19*2 and *3 alleles attenuate response to clopidogrel similarly in East Asian patients undergoing elective percutaneous coronary intervention.Correlation of high post-treatment platelet reactivity assessed by light transmittance aggregometry and the VerifyNow P2Y12 assay.Association between pulse pressure and body mass index in hypertensive and normotensive populations in the Korea National Health and Nutrition Examination Survey V, 2010-2012Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirinAccelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) studyEnhanced platelet inhibition by adjunctive cilostazol to dual antiplatelet therapy after drug-eluting stent implantation for complex lesionsInfluence of CYP2C19*2 and *3 loss-of-function alleles on the pharmacodynamic effects of standard- and high-dose clopidogrel in East Asians undergoing percutaneous coronary intervention: the results of the ACCEL-DOUBLE-2N3 studyInfluence of platelet reactivity on BARC classification in East Asian patients undergoing percutaneous coronary intervention. Results of the ACCEL-BLEED study
P50
Q33740815-2339B485-8538-4346-9752-31F8642491A6Q33751281-711386D9-AFF7-44E6-8FC4-D07FA94CA3F9Q33893919-E2BE07B5-41B7-425B-8487-4C9FD29BBFC2Q34580075-6FDDB0E2-55B4-4477-B832-248C808CE920Q34993764-08E2B05A-54FB-40D3-A508-F0D96CE6C450Q35094804-68E46803-71B5-43EE-8C05-084F92C1E285Q35566721-CE71D20E-AAEA-4810-A505-6BD25CC7A7EFQ35658419-E0767279-1A10-4E96-87A5-29D17717ACADQ35919368-8A142144-3A42-4DFF-8CF7-F454AF45B78FQ36036395-1A53CA15-BC3C-408A-83EA-C905CD8A3949Q37242615-73205765-4CFD-4D98-A605-7D0AC5A40960Q38500254-530A6CA6-3DCF-49B6-8DB8-4D11EF3154CBQ39393186-A5777107-BD4A-4389-AEB8-92BBB193B333Q39704629-F3C9B341-764B-4319-8DE4-FC9F1CF1202BQ42406128-52B16762-8389-4A6C-90C4-F2B10BE90C0EQ42409197-3C8BA45F-0882-4DF0-86A8-49B12250A8E6Q42962304-57D8535D-23A2-4245-BD49-7052CFC3B5C8Q43069767-AEEF470A-DA8A-4B9D-BB66-6509DC727D76Q43179454-7E5F4A17-F790-4BC0-B1A1-6EB9A4F688BCQ45922441-C6224C44-42B9-49DE-846C-F7D8DE98EACCQ45988227-9F7BCD10-0F6F-42C0-B8FD-F4399E099344Q46073177-DE36C650-038E-406A-8B0C-D10824EC6023Q48289712-D71E3799-01E1-43B5-8157-0632A2DC0846Q51157196-9DF0042C-7F21-4423-84DE-C8FE8F33E8B2Q51185270-D7E7D1FE-ACD5-4140-9333-B8DF59CB4CD7Q51818624-4A69365C-D9CC-4855-83E6-AAA92AA428D9Q53121548-397511FD-DE5B-42AC-A676-94B6CAC76EF1Q53286911-43F2D84B-6258-472E-BDCE-AAA2750BA59EQ53362052-F5ABDC5D-106C-44BD-AADF-CF9020D56A4EQ53375629-126A2B72-770B-4033-BF5C-FE6210632E4FQ53418798-4B137F22-836B-4FFB-967F-46A8AB0390D7Q53451175-CB038F83-75AF-49D3-A508-6863CA0CA798Q53471405-223CBBE9-ED25-4681-B01F-58F88C40A203Q57218475-448759A3-5FFE-47B9-B7B4-67B6B4C8FEF2Q82300414-55662FA4-D230-4AB5-BF0A-6B1243B08F3FQ83904183-3E611159-E84D-4289-917C-D6A50A111E0EQ85025551-FAC26696-C253-4F75-B601-D23963D30FB8Q86445069-4D7A8AA0-5A28-4396-990E-E46FC3BA7CE2Q87121785-5F32F1AA-F86E-4C19-95BF-9D51E1EF0D4B
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Choong Hwan Kwak
@ast
Choong Hwan Kwak
@en
Choong Hwan Kwak
@es
Choong Hwan Kwak
@sl
type
label
Choong Hwan Kwak
@ast
Choong Hwan Kwak
@en
Choong Hwan Kwak
@es
Choong Hwan Kwak
@sl
prefLabel
Choong Hwan Kwak
@ast
Choong Hwan Kwak
@en
Choong Hwan Kwak
@es
Choong Hwan Kwak
@sl
P106
P1153
14123355400
P31
P496
0000-0001-6035-4415